ABSTRACT: INTRODUCTION:Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations. METHODS:Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N?=?299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs. placebo; N?=?313). Logistic regression determined adjustment weights for age, body weight, sex, race, methotrexate use, psoriasis affecting???3% of body surface area, Psoriasis Area and Severity Index score, Health Assessment Questionnaire Disability Index score, presence of dactylitis and enthesitis, and previous anti-TNF therapy. Recalculated secukinumab outcomes were compared with adalimumab outcomes at weeks 12 (placebo-adjusted), 16, 24, and 48 (nonplacebo-adjusted). RESULTS:After matching, the effective sample size for FUTURE 2 was 101. Week 12 American College of Rheumatology (ACR) response rates were not significantly different between secukinumab and adalimumab. Week 16 ACR 20 and 50 response rates were higher for secukinumab 150 mg than for adalimumab (P?=?0.017, P?=?0.033), as was ACR 50 for secukinumab 300 mg (P?=?0.030). Week 24 ACR 20 and 50 were higher for secukinumab 150 mg than for adalimumab (P?=?0.001, P?=?0.019), as was ACR 20 for secukinumab 300 mg (P?=?0.048). Week 48 ACR 20 was higher for secukinumab 150 and 300 mg than for adalimumab (P?=?0.002, P?=?0.027), as was ACR 50 for secukinumab 300 mg (P?=?0.032). CONCLUSIONS:In our analysis, patients with PsA receiving secukinumab were more likely to achieve higher ACR responses through 1 year (weeks 16-48) than those treated with adalimumab. Although informative, these observations rely on a subgroup of patients from FUTURE 2 and thus should be considered interim until the ongoing head-to-head RCT EXCEED can validate these findings. FUNDING:Novartis Pharma AG.
